Bio-Techne licenses antibody to Xencor

By The Science Advisory Board staff writers

April 14, 2021 -- Bio-Techne has licensed an antibody to Xencor for therapeutic development.

Bio-Techne gave access to the antibody for use with Xencor's proprietary XmAb protein engineering technology, which aims to develop new cancer therapeutics such as bispecific antibodies and engineered cytokines. This is Bio-Techne's third licensing agreement with Xencor, the firms said.

Bio-Techne launches Abby automated western system
Bio-Techne announced that its brand ProteinSimple has released Abby, its next-generation chemiluminescence system that automates traditional western blotting.
Bio-Techne launches new product for organoid, stem cell cultures
Bio-Techne has released its new Cultrex UltiMatrix Reduced Growth Factor Basement Membrane Extract (RGF BME) to support organoid and pluripotent stem...
Luminary licenses TcBuster CAR T tech from Bio-Techne
Luminary Therapeutics has signed a license agreement with Bio-Techne for the use of its TcBuster chimeric antigen receptor (CAR) T technology for the...
Bio-Techne opens GMP manufacturing facility
Bio-Techne has opened a 61,000-sq-ft good manufacturing practice (GMP) manufacturing facility in St. Paul, MN. The space will be dedicated to large-scale...
Bio-Techne rebrands genome engineering as part of R&D Systems portfolio
Bio-Techne has rebranded its cell and gene engineering product offer as part of its R&D Systems biotechnology brand.

Copyright © 2021

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter